Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
24.36
USD
|
+2.22%
|
|
+7.17%
|
+169.17%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
957.7
|
1,115
|
1,474
|
670.6
|
2,329
|
-
|
-
|
Enterprise Value (EV)
1 |
629.5
|
709.2
|
863.7
|
670.6
|
1,608
|
1,898
|
2,329
|
P/E ratio
|
-12.4
x
|
-8.34
x
|
-6.64
x
|
-3.11
x
|
-7.77
x
|
-6.9
x
|
-7.63
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
141
x
|
120
x
|
160
x
|
70.1
x
|
173
x
|
222
x
|
27.4
x
|
EV / Revenue
|
92.8
x
|
76
x
|
93.6
x
|
70.1
x
|
119
x
|
181
x
|
27.4
x
|
EV / EBITDA
|
-14.3
x
|
-6.04
x
|
-4.87
x
|
-2.87
x
|
-6.03
x
|
-6.58
x
|
-
|
EV / FCF
|
-16.5
x
|
-7.2
x
|
-6.21
x
|
-
|
-6.91
x
|
-7.33
x
|
-10.8
x
|
FCF Yield
|
-6.07%
|
-13.9%
|
-16.1%
|
-
|
-14.5%
|
-13.6%
|
-9.23%
|
Price to Book
|
3.13
x
|
2.58
x
|
2
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,527
|
46,897
|
66,447
|
74,101
|
95,625
|
-
|
-
|
Reference price
2 |
25.52
|
23.77
|
22.19
|
9.050
|
24.36
|
24.36
|
24.36
|
Announcement Date
|
3/15/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.319
|
6.787
|
9.326
|
9.224
|
9.56
|
13.46
|
10.5
|
85.01
|
EBITDA
1 |
-
|
-43.9
|
-117.4
|
-177.5
|
-233.5
|
-266.5
|
-288.5
|
-
|
EBIT
1 |
-
|
-44.28
|
-118.1
|
-178.9
|
-235.6
|
-280.7
|
-319.4
|
-307.2
|
Operating Margin
|
-
|
-652.38%
|
-1,265.83%
|
-1,939.65%
|
-2,464.41%
|
-2,085.65%
|
-3,041.81%
|
-361.35%
|
Earnings before Tax (EBT)
1 |
-
|
-44.36
|
-118
|
-174
|
-212.2
|
-268.6
|
-315.5
|
-301.2
|
Net income
1 |
-
|
-44.36
|
-118
|
-174
|
-212.2
|
-273.7
|
-321.5
|
-301.2
|
Net margin
|
-
|
-653.53%
|
-1,265.38%
|
-1,886.33%
|
-2,219.87%
|
-2,034.12%
|
-3,061.49%
|
-354.28%
|
EPS
2 |
-4.320
|
-2.050
|
-2.850
|
-3.340
|
-2.910
|
-3.136
|
-3.533
|
-3.192
|
Free Cash Flow
1 |
-
|
-38.21
|
-98.55
|
-139.1
|
-
|
-232.6
|
-258.8
|
-215.1
|
FCF margin
|
-
|
-562.97%
|
-1,056.76%
|
-1,507.92%
|
-
|
-1,728.42%
|
-2,464.84%
|
-253.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/3/20
|
3/15/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.163
|
1.852
|
1.795
|
2.178
|
2.482
|
2.769
|
2.233
|
2.316
|
2.818
|
2.193
|
2.57
|
2.456
|
4.599
|
2.456
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.28
|
-38.55
|
-34.46
|
-46.3
|
-44.93
|
-53.22
|
-57.6
|
-52.63
|
-58.62
|
-66.74
|
-68.11
|
-69.56
|
-69.78
|
-75.89
|
-
|
Operating Margin
|
-1,353.68%
|
-2,081.37%
|
-1,919.78%
|
-2,125.76%
|
-1,810.19%
|
-1,922.17%
|
-2,579.31%
|
-2,272.63%
|
-2,080.38%
|
-3,043.46%
|
-2,649.99%
|
-2,832.31%
|
-1,517.46%
|
-3,090%
|
-
|
Earnings before Tax (EBT)
1 |
-29.27
|
-38.54
|
-34.24
|
-45.69
|
-43.6
|
-50.47
|
-52.39
|
-47.02
|
-52.36
|
-60.44
|
-64.53
|
-65.77
|
-66.65
|
-71.67
|
-
|
Net income
1 |
-29.27
|
-38.54
|
-34.24
|
-45.69
|
-43.6
|
-50.47
|
-52.39
|
-47.02
|
-52.36
|
-60.44
|
-65.59
|
-67.04
|
-68.22
|
-72.86
|
-
|
Net margin
|
-1,353.4%
|
-2,080.89%
|
-1,907.24%
|
-2,097.8%
|
-1,756.61%
|
-1,822.72%
|
-2,346.35%
|
-2,030.44%
|
-1,857.98%
|
-2,756.18%
|
-2,552.15%
|
-2,729.84%
|
-1,483.54%
|
-2,966.73%
|
-
|
EPS
2 |
-0.6800
|
-0.8400
|
-0.7100
|
-0.9200
|
-0.8200
|
-0.8800
|
-0.7400
|
-0.6600
|
-0.7100
|
-0.7900
|
-0.7743
|
-0.7643
|
-0.7743
|
-0.8171
|
-0.8500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/1/22
|
5/10/22
|
8/9/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/8/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
328
|
406
|
611
|
-
|
722
|
431
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38.2
|
-98.6
|
-139
|
-
|
-233
|
-259
|
-215
|
ROE (net income / shareholders' equity)
|
-
|
-36.8%
|
-34.3%
|
-36.3%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
8.150
|
9.210
|
11.10
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.09
|
3.74
|
2.82
|
4.23
|
0.4
|
0.42
|
0.44
|
Capex / Sales
|
-
|
16.09%
|
40.1%
|
30.6%
|
44.23%
|
2.97%
|
4%
|
0.52%
|
Announcement Date
|
4/3/20
|
3/15/21
|
3/1/22
|
2/28/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
24.36
USD Average target price
46.71
USD Spread / Average Target +91.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +169.17% | 2.33B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.35B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|